As the first quarter wrapped up, numerous sectors buzzed with fervor, but one long-dormant industry took center stage and rekindled the hopes and dreams of loyal investors. The cannabis sector not only emerged from its slumber but did so in remarkable style.
In recent weeks, several cannabis stocks skyrocketed, breathing new life into the sector with gains reaching staggering heights, some even doubling or tripling in value. Companies like Canopy Growth CGC, Tilray TLRY, and Aurora Cannabis ACB witnessed significant surges in both trading volume and stock price, prompting investors to ponder their next move.
Should caution prevail in light of the rapid and extreme upward movement, or is now the perfect moment to seize the opportunity presented by the “green gold rush”? Let’s delve deeper into the stocks in question and unravel the forces propelling their recent ascent.
Behind the Surge
What fueled this dramatic revival that jolted numerous cannabis stocks from their extended slumber? Two pivotal catalysts, both wielding substantial momentum, powered this resurgence.
Firstly, Vice President Kamala Harris reportedly voiced support for marijuana legalization during a closed-door White House meeting in March. Her call for the DEA to reclassify marijuana, labeling its Schedule I status as “absurd,” represented a groundbreaking shift. These statements marked Harris’s inaugural show of backing for federal legalization since joining the Biden administration, potentially swaying the government’s stance leading up to the presidential election.
The more potent catalyst arose when Germany legalized marijuana fully from April 1, sanctioning possession, home cultivation, and distribution within social groups. This development spells good news for investors eyeing stocks like Tilray, Cronos CRON, and Canopy Growth, especially once Germany moves to regulate commercial cannabis production and retail sales.
Key Players Making Waves
Tilray TLRY
Established in 2013, Tilray operates globally, specializing in pharmaceuticals and cannabis across regions like the US, Europe, Canada, Australia, and Latin America. Their product range spans medical and recreational cannabis offerings.
Tilray witnessed a remarkable turnaround lately, with its stock soaring nearly 43%. Notably, insiders made their first stock purchases in years, acquiring $183,210.00 in the first quarter. Analysts maintain a Hold rating based on three reviews, projecting a potential 15% upside with a consensus target price of $2.83.
Canopy Growth CGC
Canopy Growth offers an array of cannabis products catering to both medical and recreational consumers, ranging from dried cannabis to oils, capsules, and edibles.
Canopy’s recent stock surge has been exceptional, skyrocketing by 162% in the last month. The trading volume surged significantly, nearing 200 million shares over the past four sessions. However, analysts maintain a bearish outlook on the stock, with a downgraded rating and a consensus price target forecasting a potential 44% decline.
Aurora Cannabis ACB
Aurora and its subsidiaries operate globally, specializing in cannabis and derivatives across three segments: Canadian Cannabis, European Cannabis, and Plant Propagation.
Aurora witnessed significant investor interest over the past month, with its stock surging almost 40% and trading volume spiking. Market sentiment leans heavily bearish, evidenced by a substantial short interest of 24.5%, equivalent to 3.8 million shares as of March 15.
The article “Unveiling the Cannabis Craze: An Investor’s Guide” was initially published on MarketBeat.
